IMUNON (IMNN) Phase 3 OVATION 3 Trial Clears Safety Review, Continues Unmodified

IMUNON (IMNN) announced on June 23, 2026, that its Phase 3 OVATION 3 trial, evaluating its oncolytic virus immunotherapy for advanced ovarian cancer, successfully cleared a pre-planned safety review. The independent Data Monitoring Committee (DMC) recommended the trial proceed without modification. The OVATION 3 trial is a randomized, controlled study assessing IMUNON’s oncolytic virus immunotherapy, Thesarus, in combination with standard-of-care chemotherapy for patients with advanced ovarian cancer. The primary endpoint for the trial is Overall Survival (OS). This safety clearance marks a significant milestone, confirming the trial's safety profile and allowing for its uninterrupted progression towards potential efficacy data.